Search for: [Abstract = ". Preclinical pharmacological and genetic studies on cannabinoids in depression are just coming to light and they do not provide a complete picture of specificity of interaction endocannabinoid system‒depression‒antidepressants mechanism of action, yet. \; The aim of this doctoral thesis was to examine the role of the endocannabinoid system \(ie. endogenous ligands, enzymes involved in the endocannabinoids metabolism and CB receptors\) in the pathogenesis of depression with using valid animal models of depression \(Wistar Kyoto rats and removal of the olfactory bulbs\- bulbectomy\). We have also analyzed the biomarkers of the endocannabioid system following repeated vs. acute treatment with several antidepressant drugs \(IMI, ESC, TIA\) along with compounds in which antidepressant activity has been more recently demonstrated in preclinical research \(NAC, URB597\) in selected rat brain areas to determine 1\) the role in the mechanism of action of antidepressants, 2\) the stability of these effects after 10 days washout period of chronically administered drugs and 3\) the specific antidepressant drug interaction with the endocannabinoid system using selective CB1 and CB2 receptors antagonists. Another important query was to verify the following hypothesis that drug that increase the signaling of the endocannabinoid system \(by blockade of anandamide deactivation\) and possess antidepressant\-li"]

Number of results: 1